PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28795252-0	2017	IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.	irosustat	94-103	steroid sulfatase	Homo sapiens	66-83	
23797179-0	2013	A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer.	irosustat	76-85	steroid sulfatase	Homo sapiens	95-112	
18288656-3	2008	We studied the inactivation of Pseudomonas aeruginosa arylsulfatase A by a range of aryl sulfamates, including the clinical agent 667COUMATE (STX64) used to inactivate estrone sulfatase.	irosustat	130-140	steroid sulfatase	Homo sapiens	168-185	
21990014-0	2011	Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495).	irosustat	92-101	steroid sulfatase	Homo sapiens	64-81	
21990014-0	2011	Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495).	irosustat	103-108	steroid sulfatase	Homo sapiens	64-81	
21990014-0	2011	Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495).	irosustat	110-117	steroid sulfatase	Homo sapiens	64-81